Ad5-hgcc-padre vaccine - a replication-defective, recombinant adenoviral serotype 5 (ad5) encoding human guanylyl cyclase c (hgcc) and the synthetic pan dr epitope (padre), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the ad5-hgcc-padre vaccine expresses hgcc, which may induce both humoral and cellular immune responses against tumor cells expressing the hgcc antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hgcc protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. Padre is a helper t-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic t-lymphocyte (ctl) response. Also see adenovirus 5-human guanylyl cyclase c-padre vaccine
Up to date info
Latest research - Ad5-hgcc-padre vaccine
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Ad5-hgcc-padre vaccine for any updates.